Every material Form 8-K Immunome Inc. has filed with the SEC since May 12, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Immunome reported a third-quarter 2026 net loss of $85.8 million, or $0.76 per share, up from $57.5 million, or $0.65 per share, a year earlier, with no collaboration revenue in either period. Higher research and development and general and administrative spending drove the wider loss, and the company said its $461.6 million in cash and marketable securities should fund operations into 2028.
Net loss was $85.8 million for the quarter ended September 30, 2026, versus $57.5 million a year earlier; loss per share was $0.76 versus $0.65.
Research and development expenses rose to $69.5 million from $49.2 million; general and administrative expenses rose to $20.9 million from $10.9 million.
Cash, cash equivalents and marketable securities totaled $461.6 million as of September 30, 2026, which the company expects to fund operations into 2028.
The FDA set a PDUFA target action date of April 28, 2027 for varegacestat, and updated IM-1021 Phase 1 data are expected at ASH on December 14, 2026.
Immunome agreed on October 2, 2026 to amend its license agreement with Bristol-Myers Squibb, removing all milestone and royalty payment obligations and transferring certain patent rights for varegacestat and AL101 to the company. The company paid $20.0 million in cash and issued 4,425,487 shares of common stock to BMS, and it agreed to register those shares for resale, which could add supply to the market.
Amendment No. 4 dated October 2, 2026 removes all milestone and royalty payments owed to BMS under the license agreement.
Consideration was $20.0 million in cash plus 4,425,487 newly issued common shares.
The company agreed to file a resale registration statement for the shares by November 16, 2026.
The shares were issued under the Section 4(a)(2) private placement exemption and are not registered under the Securities Act.
Immunome reported second-quarter 2026 results with a net loss of $73.1 million, up from $43.4 million a year earlier, as it booked no collaboration revenue against $4.0 million in the prior-year quarter. Higher research and development and general and administrative spending drove the increase, and the company said its cash position is expected to fund operations into 2028.
Net loss of $73.1 million, or $0.65 per share, for the quarter ended June 30, 2026, versus $43.4 million, or $0.50 per share, a year earlier
Collaboration revenue was $0 versus $4.0 million in the prior-year quarter
Research and development expenses rose to $59.9 million from $40.5 million; general and administrative expenses rose to $18.3 million from $10.0 million
Cash, cash equivalents and marketable securities totaled $520.0 million as of June 30, 2026; the company expects this to fund operations into 2028
Immunome reported first-quarter 2026 results with no collaboration revenue, compared with $2.9 million a year earlier. Its net loss widened to $53.8 million from $41.6 million as research and development and general and administrative costs rose. The company said it submitted a New Drug Application for varegacestat to the FDA in April 2026 and expects its $582.7 million in cash to fund operations into 2028.
Net loss was $53.8 million for the quarter ended March 31, 2026, versus $41.6 million a year earlier.
Collaboration revenue was $0 versus $2.9 million in the first quarter of 2025.
Research and development expenses were $46.4 million, up from $36.9 million; general and administrative expenses were $13.0 million, up from $10.7 million.
Net loss per share was $0.48, compared with $0.52, on 113,136,836 weighted-average shares versus 79,410,354 a year earlier.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Immunome Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →